Van Wassenhoven Michel, Goyens Martine, Dorfman Pierre, Devos Philippe, Demangeat Jean-Louis
Coordinator of DynHom Research Project, Chastre, Belgium.
Pharmaceutical Association for Homeopathy, Wépion, Belgium.
Homeopathy. 2025 Aug;114(3):146-162. doi: 10.1055/s-0044-1787782. Epub 2024 Aug 21.
Over the past decade, research using various methods has claimed the material nature, including nanoparticles (NPs), of high homeopathic potencies. The current study aims to verify these findings using NP tracking analysis (NTA).
Six independent serial dilutions of commonly used homeopathic medicines-either soluble (, , ) or insoluble (, , )-were prepared according to European Pharmacopoeia standards. We compared the homeopathic dynamisations (DYNs) in pure water with their potentised controls and with simple dilutions (DIL) up to 30cH/10. We also tested the influence of the container (glass or PET) on the solvent controls.
We observed the presence of particles from 20 to 300-400 nm in all DYNs, DILs and controls, except in pure unstirred water. The sizes and size distributions of NPs in high homeopathic potencies were smaller than those in controls for soluble sources and larger for insoluble sources, even above 11cH. The opposite behaviour was observed in the number of NPs. When comparing DYN and DIL, the number, size, presence of aggregates or chains and brightness of NPs increased with DYNs, which was also observed above 11cH. Many NPs scattered light of low intensity, indicating the presence of material particles. The container had a significant effect on the number and size of NPs, indicating the involvement of the atmosphere and leaching processes.
Homeopathic medicines contain NPs with specific properties, even when diluted beyond Avogadro's number. Homeopathic potentisation is not a simple dilution. The starting material, the solvent used, the type of container and the manufacturing method influence the characteristics of these NPs. The nature of these NPs is not known, but most likely they are a mixture of nanobubbles and elements from the atmosphere and container, including insoluble ones.
在过去十年中,运用各种方法开展的研究宣称顺势疗法高药力制剂具有物质性质,包括纳米颗粒(NPs)。本研究旨在采用纳米颗粒追踪分析(NTA)来验证这些发现。
按照欧洲药典标准,制备了六种常用顺势疗法药物的独立系列稀释液——可溶性( 、 、 )或不溶性( 、 、 )。我们将纯水中的顺势药力增强液(DYNs)与其药力增强对照品以及高达30cH/10的简单稀释液(DIL)进行了比较。我们还测试了容器(玻璃或PET)对溶剂对照品的影响。
我们观察到,除了未搅拌的纯水外,在所有的药力增强液、稀释液和对照品中均存在粒径为20至300 - 400纳米的颗粒。对于可溶性来源,高顺势药力制剂中纳米颗粒的尺寸和尺寸分布比对照品中的小;对于不溶性来源,即使在高于11cH时,其尺寸和尺寸分布也比对照品中的大。纳米颗粒数量呈现相反的情况。比较药力增强液和稀释液时,纳米颗粒的数量、尺寸、聚集体或链的存在以及亮度随药力增强液增加,在高于11cH时也观察到这种情况。许多纳米颗粒散射低强度光,表明存在物质颗粒。容器对纳米颗粒的数量和尺寸有显著影响,表明大气和浸出过程的参与。
顺势疗法药物含有具有特定性质的纳米颗粒,即使稀释超过阿伏伽德罗数。顺势药力增强并非简单稀释。起始原料、所用溶剂、容器类型和制造方法会影响这些纳米颗粒的特性。这些纳米颗粒的性质尚不清楚,但很可能它们是纳米气泡与来自大气和容器的元素(包括不溶性元素)的混合物。